Favipiravir-induced cutaneous adverse reactions in patients infected with COVID-19.
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
24
09
2021
accepted:
27
09
2021
pubmed:
1
10
2021
medline:
11
3
2022
entrez:
30
9
2021
Statut:
ppublish
Résumé
Favipiravir (FVP) has been used for treatment of COVID-19 in many countries. We analysed the incidence of FVP-induced cutaneous adverse reactions (CARs) in patients infected with COVID-19 who were hospitalized at Bamrasnaradura Infectious Diseases Institute, a principal centre of emerging infectious disease in Thailand, and who presented with cutaneous eruption following FVP prescription. We identified five cases of FVP-induced CARs: two patients with maculopapular rash, two with urticarial rash, and one with Stevens-Johnson syndrome. The median interval between FVP treatment and rash occurrence was 7 days and the mean duration of the rash was 5 days. This report highlights that FVP can induce CARs, particularly eruptions, in COVID-19-infected patients. Clinicians should be aware of this possible drug-related allergy, and it should be excluded as a cause of rash during FVP treatment of COVID-19.
Identifiants
pubmed: 34592006
doi: 10.1111/ced.14953
pmc: PMC8653311
doi:
Substances chimiques
Amides
0
Antiviral Agents
0
Pyrazines
0
favipiravir
EW5GL2X7E0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
573-577Informations de copyright
© 2021 British Association of Dermatologists.
Références
Br J Dermatol. 2020 Jul;183(1):71-77
pubmed: 32348545
Sci Rep. 2021 May 26;11(1):11022
pubmed: 34040117
J Am Acad Dermatol. 2020 Dec;83(6):1738-1748
pubmed: 32777318
CMAJ. 2018 Apr 30;190(17):E532-E538
pubmed: 29712672
J Am Acad Dermatol. 2020 Oct;83(4):1118-1129
pubmed: 32622888
JAAD Int. 2021 Mar;2:119-133
pubmed: 33479703